ArticleBlood2018

An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.

Franck Morschhauser et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.